These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36353535)

  • 21. Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis.
    Kim HI; An J; Han S; Shim JH
    Clin Mol Hepatol; 2023 Oct; 29(4):1013-1028. PubMed ID: 37403319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microwave ablation versus radiofrequency ablation for subcapsular hepatocellular carcinoma: a propensity score-matched study.
    Zheng H; Liu K; Yang Y; Liu B; Zhao X; Chen Y; Feng Y; Meng M; Tan X; Zhu Q
    Eur Radiol; 2022 Jul; 32(7):4657-4666. PubMed ID: 35092477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of surgical resection versus radiofrequency ablation in very-early-stage hepatocellular carcinoma: a propensity score matching analysis.
    Li YC; Chen PH; Yeh JH; Hsiao P; Lo GH; Tan T; Cheng PN; Lin HY; Chen YS; Hsieh KC; Hsieh PM; Lin CW
    BMC Gastroenterol; 2021 Nov; 21(1):418. PubMed ID: 34749663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection.
    Feng Y; Wu H; Huang DQ; Xu C; Zheng H; Maeda M; Zhao X; Wang L; Xiao F; Lv H; Liu T; Qi J; Li J; Zhong N; Wang C; Feng H; Liang B; Ren W; Qin C; Nguyen MH; Zhu Q
    Eur Radiol; 2020 Nov; 30(11):6357-6368. PubMed ID: 32529568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study.
    Gory I; Fink M; Bell S; Gow P; Nicoll A; Knight V; Dev A; Rode A; Bailey M; Cheung W; Kemp W; Roberts SK;
    Scand J Gastroenterol; 2015 May; 50(5):567-76. PubMed ID: 25615260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.
    Doyle A; Gorgen A; Muaddi H; Aravinthan AD; Issachar A; Mironov O; Zhang W; Kachura J; Beecroft R; Cleary SP; Ghanekar A; Greig PD; McGilvray ID; Selzner M; Cattral MS; Grant DR; Lilly LB; Selzner N; Renner EL; Sherman M; Sapisochin G
    J Hepatol; 2019 May; 70(5):866-873. PubMed ID: 30615906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can "no-touch" radiofrequency ablation for hepatocellular carcinoma improve local tumor control? Systematic review and meta-analysis.
    Kim TH; Lee JM; Lee DH; Joo I; Park SJ; Yoon JH
    Eur Radiol; 2023 Jan; 33(1):545-554. PubMed ID: 35907024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome of transcatheter arterial chemoembolization after radiofrequency ablation as a combined therapy for Chinese patients with hepatocellular carcinoma.
    Xu RC; Liu HC; Li JL; Li K; Ou SY; Yu ZY; Kong Y; Ma GA; Shao WS
    Curr Med Res Opin; 2015 Aug; 31(8):1553-60. PubMed ID: 26067770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study.
    Yan L; Ren Y; Qian K; Kan X; Zhang H; Chen L; Liang B; Zheng C
    BMC Gastroenterol; 2021 Apr; 21(1):182. PubMed ID: 33879085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma.
    Lin CC; Lui KW; Chen WT; Hsieh YC; Cheng YT; Teng W; Lin SM
    Eur Radiol; 2021 Nov; 31(11):8649-8661. PubMed ID: 33895858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microwave ablation is as effective as radiofrequency ablation for very-early-stage hepatocellular carcinoma.
    Xu Y; Shen Q; Wang N; Wu PP; Huang B; Kuang M; Qian GJ
    Chin J Cancer; 2017 Jan; 36(1):14. PubMed ID: 28103953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiofrequency ablation in the treatment of hepatocellular carcinoma.
    Deng Q; He M; Fu C; Feng K; Ma K; Zhang L
    Int J Hyperthermia; 2022; 39(1):1052-1063. PubMed ID: 35944905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overall Survival of Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation (RFA) Treatment: a Retrospective Cohort Study from Two Referral Hospitals in Indonesia.
    Sulaiman AS; Gani RA; Hasan I; Lesmana CRA; Kurniawan J; Jasirwan COM; Kalista KF; Nababan SHH; Aprilicia G; Lesmana LA
    J Gastrointest Cancer; 2022 Sep; 53(3):632-640. PubMed ID: 34379264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computed tomographic-guided radiofrequency ablation of recurrent or residual hepatocellular carcinomas around retained iodized oil after transarterial chemoembolization.
    Koh YH; Choi JI; Kim HB; Kim MJ
    Korean J Radiol; 2013; 14(5):733-42. PubMed ID: 24043966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression.
    Cao S; Zou Y; Lyu T; Fan Z; Guan H; Song L; Tong X; Wang J
    Int J Hyperthermia; 2022; 39(1):1-7. PubMed ID: 34937501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Local tumor control of intermediate and advanced stage hepatocellular carcinoma after local ablative treatment with image-guided interstitial high-dose-rate brachytherapy: A subgroup analysis of 286 HCC nodules.
    Heinze C; Damm R; Othmer M; Thormann M; Surov A; Hass P; Seidesticker R; Seidensticker M; Ricke J; Powerski M; Pech M; Omari J
    Brachytherapy; 2023; 22(2):231-241. PubMed ID: 36697267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation.
    Wang X; Liang H; Lu Z
    Minim Invasive Ther Allied Technol; 2020 Dec; 29(6):344-352. PubMed ID: 31375044
    [No Abstract]   [Full Text] [Related]  

  • 38. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma.
    Cui J; Wang N; Zhao H; Jin H; Wang G; Niu C; Terunuma H; He H; Li W
    Int J Cancer; 2014 Jan; 134(2):342-51. PubMed ID: 23825037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple-Electrode Switching-Based Radiofrequency Ablation vs. Conventional Radiofrequency Ablation for Single Early-Stage Hepatocellular Carcinoma Ranging From 2 to 5 Cm.
    Huang GL; Liu M; Zhang XE; Liu BX; Xu M; Lin MX; Kuang M; Lu MD; Xie XY
    Front Oncol; 2020; 10():1150. PubMed ID: 32793484
    [No Abstract]   [Full Text] [Related]  

  • 40. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival.
    Lee MW; Kang D; Lim HK; Cho J; Sinn DH; Kang TW; Song KD; Rhim H; Cha DI; Lu DSK
    Eur Radiol; 2020 Apr; 30(4):2391-2400. PubMed ID: 31900708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.